Network-based approach to identify prognostic biomarkers for estrogen receptor–positive breast cancer treatment with tamoxifen

References

• Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 2013; 73:4885-97; PMID:23737486; http://dx.doi.org/10.1158/0008-5472.CAN-12-4081
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int Du Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
   PubMed Web of Science ®Google Scholar
• Vendrell JA, Ghayad S, Ben-Larbi S, Dumontet C, Mechti N, Cohen PA. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 2007; 26:4656-67; PMID:17297453; http://dx.doi.org/10.1038/sj.onc.1210269
   PubMed Web of Science ®Google Scholar
• Stuart JM, Segal E, Koller D, Kim SK. A gene-coexpression network for global discovery of conserved genetic modules. Science 2003; 302:249-55; PMID:12934013; http://dx.doi.org/10.1126/science.1087447
   PubMed Web of Science ®Google Scholar
• Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ, Thibodeau SN. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 2009; 69:9490-7; PMID:19996289; http://dx.doi.org/10.1158/0008-5472.CAN-09-2183
   PubMed Web of Science ®Google Scholar
• Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A 2006; 103:17402-7; PMID:17090670; http://dx.doi.org/10.1073/pnas.0608396103
   PubMed Web of Science ®Google Scholar
• Ivliev AE, t Hoen PA, Sergeeva MG. Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma. Cancer Res 2010; 70:10060-70; PMID:21159630; http://dx.doi.org/10.1158/0008-5472.CAN-10-2465
   PubMed Web of Science ®Google Scholar
• Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10:28; PMID:18662380; http://dx.doi.org/10.1186/bcr2124
   PubMed Web of Science ®Google Scholar
• Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis 2013; 34:2300-8; PMID:23740839; http://dx.doi.org/10.1093/carcin/bgt208
   PubMed Web of Science ®Google Scholar
• Nishida Y, Yoshioka M, St-Amand J. Regulation of hypothalamic gene expression by glucocorticoid: implications for energy homeostasis. Physiol Genomics 2006; 25:96-104; PMID:16368873; http://dx.doi.org/10.1152/physiolgenomics.00232.2005
   PubMed Web of Science ®Google Scholar
• Gonzalez-Malerva L, Park J, Zou L, Hu Y, Moradpour Z, Pearlberg J, Sawyer J, Stevens H, Harlow E, LaBaer J. High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A 2011; 108:2058-63; PMID:21233418; http://dx.doi.org/10.1073/pnas.1018157108
   PubMed Web of Science ®Google Scholar
• Castellano I, Chiusa L, Vandone AM, Beatrice S, Goia M, Donadio M, Arisio R, Muscara F, Durando A, Viale G, et al. A simple and reproducible prognostic index in luminal ER-positive breast cancers. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2013; 24:2292-7; PMID:23709174; http://dx.doi.org/10.1093/annonc/mdt183
   PubMed Web of Science ®Google Scholar
• (EBCTCG). EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717; PMID:15894097; http://dx.doi.org/10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998; 90:1371-88; PMID:9747868; http://dx.doi.org/10.1093/jnci/90.18.1371
   PubMed Web of Science ®Google Scholar
• Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006; 66:7334-40; PMID:16849584; http://dx.doi.org/10.1158/0008-5472.CAN-05-4269
   PubMed Web of Science ®Google Scholar
• Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66:11954-66; PMID:17178894; http://dx.doi.org/10.1158/0008-5472.CAN-06-1666
   PubMed Web of Science ®Google Scholar
• Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008; 14:1744-52; PMID:18347175; http://dx.doi.org/10.1158/1078-0432.CCR-07-1833
   PubMed Web of Science ®Google Scholar
• Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23:732-40; PMID:15681518; http://dx.doi.org/10.1200/JCO.2005.05.145
   PubMed Web of Science ®Google Scholar
• Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14:1067-76; PMID:24035531; http://dx.doi.org/10.1016/S1470-2045(13)70387-5
   PubMed Web of Science ®Google Scholar
• Guo S, Li Y, Tong Q, Gu F, Zhu T, Fu L, Yang S. deltaEF1 down-regulates ER-alpha expression and confers tamoxifen resistance in breast cancer. PloS one 2012; 7:e52380; PMID:23285017; http://dx.doi.org/10.1371/journal.pone.0052380
   PubMed Web of Science ®Google Scholar
• Johansson HJ, Sanchez BC, Mundt F, Forshed J, Kovacs A, Panizza E, Hultin-Rosenberg L, Lundgren B, Martens U, Mathe G, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun 2013; 4:2175; PMID:23868472; http://dx.doi.org/10.1038/ncomms3175
   PubMed Web of Science ®Google Scholar
• Gao T, Han Y, Yu L, Ao S, Li Z, Ji J. CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. PloS One 2014; 9:e91771; PMID:24622579; http://dx.doi.org/10.1371/journal.pone.0091771
   PubMed Web of Science ®Google Scholar
• Ding K, Li W, Zou Z, Zou X, Wang C. CCNB1 is a prognostic biomarker for ER+ breast cancer. Med Hypotheses 2014; 83:359-64; PMID:25044212; http://dx.doi.org/10.1016/j.mehy.2014.06.013
   PubMed Web of Science ®Google Scholar
• Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5:607-16; PMID:15193263; http://dx.doi.org/10.1016/j.ccr.2004.05.015
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 2004; 351:2817-26; PMID:15591335; http://dx.doi.org/10.1056/NEJMoa041588
   PubMed Web of Science ®Google Scholar
• Xu XL, Chen SZ, Chen W, Zheng WH, Xia XH, Yang HJ, Li B, Mao WM. The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis. Breast Cancer Res Treat 2013; 139:329-39; PMID:23670132; http://dx.doi.org/10.1007/s10549-013-2563-5
   PubMed Web of Science ®Google Scholar
• Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG Jr, Toledo S, et al. Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer J Int Du Cancer 2008; 122:807-15; PMID:17960622; http://dx.doi.org/10.1002/ijc.23189
   PubMed Web of Science ®Google Scholar
• Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res 2008; 86:48-60; PMID:17722061; http://dx.doi.org/10.1002/jnr.21471
   PubMed Web of Science ®Google Scholar
• Pickard MR, Green AR, Ellis IO, Caldas C, Hedge VL, Mourtada-Maarabouni M, Williams GT. Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res 2009; 11:11; PMID:19671159; http://dx.doi.org/10.1186/bcr2350
   PubMed Web of Science ®Google Scholar
• Lin ML, Park JH, Nishidate T, Nakamura Y, Katagiri T. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res 2007; 9:R17; PMID:17280616;
   PubMed Web of Science ®Google Scholar
• Li Y, Tang H, Sun Z, Bungum AO, Edell ES, Lingle WL, Stoddard SM, Zhang M, Jen J, Yang P, et al. Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients. Lung Cancer 2013; 80:91-8; PMID:23357462; http://dx.doi.org/10.1016/j.lungcan.2012.12.022
   PubMed Web of Science ®Google Scholar
• Chen X, Thiaville MM, Chen L, Stoeck A, Xuan J, Gao M, Shih Ie M, Wang TL. Defining NOTCH3 target genes in ovarian cancer. Cancer Res 2012; 72:2294-303; PMID:22396495; http://dx.doi.org/10.1158/0008-5472.CAN-11-2181
   PubMed Web of Science ®Google Scholar
• Pavlou MP, Dimitromanolakis A, Martinez-Morillo E, Smid M, Foekens JA, Diamandis EP. Integrating meta-analysis of microarray data and targeted proteomics for biomarker identification: application in breast cancer. J Proteome Res 2014; 13:2897-909; PMID:24799281; http://dx.doi.org/10.1021/pr500352e
   PubMed Web of Science ®Google Scholar
• Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer 2014; 14:1471-2407; PMID:24444383; http://dx.doi.org/10.1186/1471-2407-14-32
   PubMed Web of Science ®Google Scholar
• Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer 2011; 10:15; PMID:21314937; http://dx.doi.org/10.1186/1476-4598-10-15
   PubMed Web of Science ®Google Scholar
• Putluri N, Maity S, Kommangani R, Creighton CJ, Putluri V, Chen F, Nanda S, Bhowmik SK, Terunuma A, Dorsey T, et al. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia 2014; 16:390-402; PMID:25016594; http://dx.doi.org/10.1016/j.neo.2014.05.007
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25:1239-46; PMID:17401012; http://dx.doi.org/10.1200/JCO.2006.07.1522
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008; 9:1471-2164; PMID:18498629; http://dx.doi.org/10.1186/1471-2164-9-239
   PubMed Web of Science ®Google Scholar
• Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005; 102:13550-5; PMID:16141321; http://dx.doi.org/10.1073/pnas.0506230102
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98:262-72; PMID:16478745; http://dx.doi.org/10.1093/jnci/djj052
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27:1160-7; PMID:19204204; http://dx.doi.org/10.1200/JCO.2008.18.1370
   PubMed Web of Science ®Google Scholar
• Miller J, Cai C, Langfelder P, Geschwind D, Kurian S, Salomon D, Horvath S. Strategies for aggregating gene expression data: the collapseRows R function. BMC Bioinformatics 2011; 12:322; PMID:21816037; http://dx.doi.org/10.1186/1471-2105-12-322
   PubMed Web of Science ®Google Scholar
• Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 2005; 4:Article17; PMID:16646834; http://dx.doi.org/10.2202/1544-6115.1128
   PubMed Web of Science ®Google Scholar
• Dennis G, Sherman B, Hosack D, Yang J, Gao W, Lane HC, Lempicki R. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4:P3; PMID:12734009; http://dx.doi.org/10.1186/gb-2003-4-5-p3
   PubMed Web of Science ®Google Scholar